U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06934889) titled 'Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma' on April 11.
Brief Summary: The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
Study Start Date: April 07
Study Type: INTERVENTIONAL
Condition:
Glioblastoma
Gliosarcoma
Intervention:
DRUG: ERAS-801
will be administered orally at the assigned dose once daily starting on Cycle 1 Day 1.
DRUG: ABBV-637
will be administered intravenously over one hour (+/- 10 min) once every 28 days on...